date:May 31, 2022
r was grilled over the agencys delay in responding to a whistleblower who months ago revealed a series of poor safety practices at Abbotts Sturgis facility.
Following the death of two infants and a number of hospitalizations, Abbott recalled products manufactured at the facility. A subsequent FDA investigation revealed damning observations, including the absence of a process control system that could ensure infant formula does not become adulterated. Five environmental subsamples were positive